


**Patient**  
 Name: **T** Vorname: **C**  
 Geb.Datum: \_\_\_\_\_  
 einsendender Arzt: Dr. S  
 Eingangsdatum: 28.05.2002

MD 1461-02  
1'080 K/mL

CPT  
EDTABlut  
Serum  
Plasmathek


Patient details;  
address of sending  
physician.

**"PhenoTecT" Resistenz-Report**



direct visual resistance overview:  
green= sensitive  
red = high risk of resistance

SIR classification analogous to micro-biological antibiogram.




Direct report of algorithm independent phenotypic 'resistance factors' IC<sub>50</sub> patient virus/IC<sub>50</sub> Reference virus.

**Kommentar:** Protease Hemmer: hohes Resistenzrisiko für Crixivan, Viracept, Norvir und Fortovase nachgewiesen! Verminderte Aktivität von Kaletra zu erwarten.  
 RT Hemmer: hohes Resistenzrisiko für 3TC nachgewiesen! Verminderte Aktivität von Ziagen zu erwarten.

Expert's Comments to complement the phenotypic analysis:  
 - therapeutic recommendation,  
 - background information,  
 - further properties of the virus.

Basel, 10.06.2002  
 Unterschrift:

Dr. F. Hamy (techn. verantwortlich) Dr. Th. Klimkait (medizin. verantwortlich)



Sample report is 50% of original size.

- Direct visualization of all analytical details (percentage of inhibition in triplicate for each inhibitor concentration)  
 - 18 data points per inhibitor

